EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program

Rajesh Patel iD, Dennis Brooks, Elise Gorseth, Rachel Moate, Alexis Hofherr, Chris Kell, Gabriela Luporini Saraiva iD, Hitesh Pandya, Martin Jenkins, Ioannis Psallidas

Biologics: Targets and Therapy · 2026-07 · Volume 20 · 1-11

DOI: 10.2147/btt.s581444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biologics: Targets and Therapy, 2026-07. Verfasst von Rajesh Patel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

COPDasthmaatopic dermatitisbiologicsdiabetic kidney diseasesafetytozorakimab

Autor:innen und Institutionen

  • Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Patient Safety Pharmacovigilance, AstraZeneca, Gaithersburg, MD, USA.
  • Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Late-stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

ORCID-Profile: Rajesh Patel, Gabriela Luporini Saraiva

Zitieren

APA

Patel, R., Brooks, D., Gorseth, E., Moate, R., Hofherr, A., Kell, C., Luporini Saraiva, G., Pandya, H., Jenkins, M., & Psallidas, I. (2026). Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. Biologics: Targets and Therapy, Volume 20, 1-11. https://doi.org/10.2147/btt.s581444

Vancouver

Patel R, Brooks D, Gorseth E, Moate R, Hofherr A, Kell C, et al. Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. Biologics: Targets and Therapy. 2026;Volume 20:1-11. doi:10.2147/btt.s581444

BibTeX
@article{Patel2026,
  author = {Patel, Rajesh and Brooks, Dennis and Gorseth, Elise and Moate, Rachel and Hofherr, Alexis and Kell, Chris and Luporini Saraiva, Gabriela and Pandya, Hitesh and Jenkins, Martin and Psallidas, Ioannis},
  title = {Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program},
  journal = {Biologics: Targets and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/btt.s581444}
}
Kostenlos starten →